2017 Press Releases

Date Title  
Toggle Summary West Pharmaceutical Services, Inc. to Broadcast Review of Third Quarter Earnings Live Over the Internet
LIONVILLE, Pa., Oct. 15 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced today that it will release third quarter financial results before the open of the market on Wednesday, October 17, 2001. William G. Little, Chairman and Chief Executive Officer and Dr. Donald E.
West Pharmaceutical Services, Inc. to Broadcast Review of Third Quarter Earnings Live Over the Internet
LIONVILLE, Pa., Oct. 15 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced today that it will release third quarter financial results before the open of the market on Wednesday, October 17, 2001. William G. Little, Chairman and Chief Executive Officer and Dr. Donald E.
Toggle Summary West Pharmaceutical Services, Inc. Announces Dividend
LIONVILLE, Pa., Oct 5, 2001 /PRNewswire via COMTEX/ -- West Pharmaceutical Services, Inc. announced that its Board of Directors has declared a dividend of $.19 per share for the fourth quarter of 2001 payable November 7, 2001 to shareholders of record October 24, 2001.
West Pharmaceutical Services, Inc. Announces Dividend
LIONVILLE, Pa., Oct 5, 2001 /PRNewswire via COMTEX/ -- West Pharmaceutical Services, Inc. announced that its Board of Directors has declared a dividend of $.19 per share for the fourth quarter of 2001 payable November 7, 2001 to shareholders of record October 24, 2001.
Toggle Summary West Pharmaceutical Services Initiates U.S. Clinical Trials of Novel Site-Specific Oral Therapy for Gastrointestinal Disorders
LIONVILLE, Pa., Sep 24, 2001 /PRNewswire/ -- Proprietary Oral Delivery System, TARGIT-Budesonide, to Potentially Improve Effectiveness and Reduce Side-Effects for Treatment of Inflammatory Bowel Diseases, Ulcerative Colitis and Crohn's Disease West Pharmaceutical Services, Inc.
West Pharmaceutical Services Initiates U.S. Clinical Trials of Novel Site-Specific Oral Therapy for Gastrointestinal Disorders
LIONVILLE, Pa., Sep 24, 2001 /PRNewswire/ -- Proprietary Oral Delivery System, TARGIT-Budesonide, to Potentially Improve Effectiveness and Reduce Side-Effects for Treatment of Inflammatory Bowel Diseases, Ulcerative Colitis and Crohn's Disease West Pharmaceutical Services, Inc.
Toggle Summary West Pharmaceutical Services, Inc. Announces Death of J. Roffe Wike, II, Director
LIONVILLE, Pa., Sep 13, 2001 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced that J. Roffe Wike, II died at home on September 10th, 2001 following a brief illness. Mr. Wike was a member of the Company's Board of Directors for almost 40 years and the son of one of the
West Pharmaceutical Services, Inc. Announces Death of J. Roffe Wike, II, Director
LIONVILLE, Pa., Sep 13, 2001 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced that J. Roffe Wike, II died at home on September 10th, 2001 following a brief illness. Mr. Wike was a member of the Company's Board of Directors for almost 40 years and the son of one of the
Toggle Summary West Pharmaceutical Services Announces Successful Completion Of Euro Conversion
LIONVILLE, Pa., Aug. 6 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced that it has successfully completed conversion of its business processes and systems in the Eurozone from national currencies to the Euro. The company now has the capabilities to offer full business
West Pharmaceutical Services Announces Successful Completion Of Euro Conversion
LIONVILLE, Pa., Aug. 6 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced that it has successfully completed conversion of its business processes and systems in the Eurozone from national currencies to the Euro. The company now has the capabilities to offer full business
Toggle Summary West Pharmaceutical Services, Inc. Clarifies Statements Regarding Debiotech, S.A. and Debiopharm, S.A
LIONVILLE, Pa., July 24 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today clarified references to Debiotech, S.A. and Debiopharm, S.A. that were contained in recent company press releases. In a release issued July 17, 2001, West Pharmaceutical Services referred to Debiotech, S.A.
West Pharmaceutical Services, Inc. Clarifies Statements Regarding Debiotech, S.A. and Debiopharm, S.A
LIONVILLE, Pa., July 24 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today clarified references to Debiotech, S.A. and Debiopharm, S.A. that were contained in recent company press releases. In a release issued July 17, 2001, West Pharmaceutical Services referred to Debiotech, S.A.
Toggle Summary West Pharmaceutical Services, Inc. Announces Second-Quarter and Six-Month Results
LIONVILLE, Pa., Jul 19, 2001 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced results for the second quarter and six months ended June 30, 2001. Net sales for the second quarter increased 3% to $117.2 million compared to the $113.6 million reported in the second
West Pharmaceutical Services, Inc. Announces Second-Quarter and Six-Month Results
LIONVILLE, Pa., Jul 19, 2001 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced results for the second quarter and six months ended June 30, 2001. Net sales for the second quarter increased 3% to $117.2 million compared to the $113.6 million reported in the second
Toggle Summary West Pharmaceutical Services Secures U.S. Marketing Rights for Novel Single Dose Drug Reconstitution System
LIONVILLE, Pa., July 17 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced the first significant commercial milestone in its new initiative to manufacture and market an advanced single dose delivery drug reconstitution system. Debiopharm, S.A., a Swiss-based pharmaceutical
West Pharmaceutical Services Secures U.S. Marketing Rights for Novel Single Dose Drug Reconstitution System
LIONVILLE, Pa., July 17 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced the first significant commercial milestone in its new initiative to manufacture and market an advanced single dose delivery drug reconstitution system. Debiopharm, S.A., a Swiss-based pharmaceutical
Toggle Summary West Pharmaceutical Services Announces Agreement With Solvay Pharmaceuticals To License Novel Nasal Delivery Technology For Leading Influenza Vaccine
LIONVILLE, Pa., Jul 2, 2001 /PRNewswire/ -- West Pharmaceutical Services' Patented ChiSys(TM) Nasal Delivery System to be Developed for Influvac(TM) Vaccine, Now Used by Millions of Patients in More Than 35 Countries West Pharmaceutical Services, Incorporated (NYSE: WST) today announced completion
West Pharmaceutical Services Announces Agreement With Solvay Pharmaceuticals To License Novel Nasal Delivery Technology For Leading Influenza Vaccine
LIONVILLE, Pa., Jul 2, 2001 /PRNewswire/ -- West Pharmaceutical Services' Patented ChiSys(TM) Nasal Delivery System to be Developed for Influvac(TM) Vaccine, Now Used by Millions of Patients in More Than 35 Countries West Pharmaceutical Services, Incorporated (NYSE: WST) today announced completion
Toggle Summary West Pharmaceutical Services, Inc. Announces Dividend
LIONVILLE, Pa., June 19 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced that its Board of Directors has declared a dividend of $.18 per share for the third quarter of 2001 payable August 1, 2001 to shareholders of record July 18, 2001.
West Pharmaceutical Services, Inc. Announces Dividend
LIONVILLE, Pa., June 19 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced that its Board of Directors has declared a dividend of $.18 per share for the third quarter of 2001 payable August 1, 2001 to shareholders of record July 18, 2001.
Toggle Summary West Pharmaceutical Services, Inc. Announces Promotion of Linda R. Altemus To Vice President, Finance and Administration
LIONVILLE, Pa., May 11 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced the promotion of Linda R. Altemus, 49, to the position of Vice President, Finance and Administration, effective June 30, 2001. In her new role, Ms. Altemus will oversee the Company's financial and
West Pharmaceutical Services, Inc. Announces Promotion of Linda R. Altemus To Vice President, Finance and Administration
LIONVILLE, Pa., May 11 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced the promotion of Linda R. Altemus, 49, to the position of Vice President, Finance and Administration, effective June 30, 2001. In her new role, Ms. Altemus will oversee the Company's financial and
Toggle Summary West Pharmaceutical Services Concludes Strategic Review
LIONVILLE, Pa., May 1 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced the conclusion of its review of strategic alternatives which it was conducting with the assistance of its financial advisor UBS Warburg LLC. The Board of Directors concluded that there is a growing
West Pharmaceutical Services Concludes Strategic Review
LIONVILLE, Pa., May 1 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced the conclusion of its review of strategic alternatives which it was conducting with the assistance of its financial advisor UBS Warburg LLC. The Board of Directors concluded that there is a growing
Toggle Summary West Pharmaceutical Services Announces Improved First Quarter Results
LIONVILLE, Pa., April 19 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced improved results for the first quarter ended March 31, 2001. Net income for the first quarter was $5.4 million, or $0.38 per share, compared with net income of $5.1 million, or $0.35 per share,
West Pharmaceutical Services Announces Improved First Quarter Results
LIONVILLE, Pa., April 19 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced improved results for the first quarter ended March 31, 2001. Net income for the first quarter was $5.4 million, or $0.38 per share, compared with net income of $5.1 million, or $0.35 per share,
Toggle Summary West Pharmaceutical Services, Inc. Announces Dividend
LIONVILLE, Pa., March 12 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced that its Board of Directors has declared a dividend of $.18 per share for the second quarter of 2001 payable May 2, 2001 to shareholders of record April 18, 2001.
West Pharmaceutical Services, Inc. Announces Dividend
LIONVILLE, Pa., March 12 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced that its Board of Directors has declared a dividend of $.18 per share for the second quarter of 2001 payable May 2, 2001 to shareholders of record April 18, 2001.
Toggle Summary West Pharmaceutical Services, Inc. Announces Fourth Quarter and Full Year 2000 Results
LIONVILLE, Pa., Feb. 27 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today reported financial results for the fourth quarter and year-ended December 31, 2000. The results are consistent with guidance provided by management on January 29, 2001.
West Pharmaceutical Services, Inc. Announces Fourth Quarter and Full Year 2000 Results
LIONVILLE, Pa., Feb. 27 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today reported financial results for the fourth quarter and year-ended December 31, 2000. The results are consistent with guidance provided by management on January 29, 2001.
Toggle Summary West Pharmaceutical Services to Present at UBS Warburg Global Healthcare Services Conference
LIONVILLE, Pa., Feb. 5 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced that it will present at the UBS Warburg Global Healthcare Services Conference on Tuesday, February 6, 2001 at 2:00 p.m. at the New York Plaza Hotel. Dr. Donald E.
West Pharmaceutical Services to Present at UBS Warburg Global Healthcare Services Conference
LIONVILLE, Pa., Feb. 5 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced that it will present at the UBS Warburg Global Healthcare Services Conference on Tuesday, February 6, 2001 at 2:00 p.m. at the New York Plaza Hotel. Dr. Donald E.
Toggle Summary West Pharmaceutical Services Comments on Expected Fourth Quarter and Full Year 2000 Results
LIONVILLE, Pa., Jan. 29 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today commented on expected results for the fourth quarter and year ended December 31, 2000. As disclosed previously, soft market conditions and project delays resulted in lower sales volumes in the contract
West Pharmaceutical Services Comments on Expected Fourth Quarter and Full Year 2000 Results
LIONVILLE, Pa., Jan. 29 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today commented on expected results for the fourth quarter and year ended December 31, 2000. As disclosed previously, soft market conditions and project delays resulted in lower sales volumes in the contract
Toggle Summary West Pharmaceutical Services, Inc. Announces Dividend
LIONVILLE, Pa., Dec. 12 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced that its Board of Directors has declared a dividend of $.18 per share for the first quarter of 2001 payable February 7, 2001 to shareholders of record January 24, 2001.
West Pharmaceutical Services, Inc. Announces Dividend
LIONVILLE, Pa., Dec. 12 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced that its Board of Directors has declared a dividend of $.18 per share for the first quarter of 2001 payable February 7, 2001 to shareholders of record January 24, 2001.
Toggle Summary West Pharmaceutical Services, Inc. Announces Corporate Initiatives To Streamline Operations
LIONVILLE, Pa., Nov. 16 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced that its Board of Directors approved corporate initiatives designed to streamline operations and improve efficiencies. The Company stated that these initiatives are independent of UBS Warburg's
West Pharmaceutical Services, Inc. Announces Corporate Initiatives To Streamline Operations
LIONVILLE, Pa., Nov. 16 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced that its Board of Directors approved corporate initiatives designed to streamline operations and improve efficiencies. The Company stated that these initiatives are independent of UBS Warburg's
Toggle Summary West Pharmaceutical Services Reports Third Quarter Results; Commences Strategic Review; Announces Drug Delivery Licensing Agreements
LIONVILLE, Pa., Oct. 16 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today reported net income of $4.6 million, or $0.32 per share, compared with third quarter 1999 net income of $8.6 million, or $0.58 per share. In the Device Product Development segment, strong sales growth in
West Pharmaceutical Services Reports Third Quarter Results; Commences Strategic Review; Announces Drug Delivery Licensing Agreements
LIONVILLE, Pa., Oct. 16 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today reported net income of $4.6 million, or $0.32 per share, compared with third quarter 1999 net income of $8.6 million, or $0.58 per share. In the Device Product Development segment, strong sales growth in
Toggle Summary West Pharmaceutical Services, Inc. Announces Dividend Increase
LIONVILLE, Pa., Aug. 1 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced that its Board of Directors has declared a dividend of $.18 per share for the fourth quarter of 2000 payable November 1, 2000 to shareholders of record on October 18, 2000.
West Pharmaceutical Services, Inc. Announces Dividend Increase
LIONVILLE, Pa., Aug. 1 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced that its Board of Directors has declared a dividend of $.18 per share for the fourth quarter of 2000 payable November 1, 2000 to shareholders of record on October 18, 2000.
Toggle Summary West Pharmaceutical Services, Inc. Announces Second Quarter And Six Month Results
LIONVILLE, Pa., July 20 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced results for the second quarter and six months ended June 30, 2000. Net sales for the second quarter were $112.7 million compared to the $124.4 million reported in the second quarter of 1999.
West Pharmaceutical Services, Inc. Announces Second Quarter And Six Month Results
LIONVILLE, Pa., July 20 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced results for the second quarter and six months ended June 30, 2000. Net sales for the second quarter were $112.7 million compared to the $124.4 million reported in the second quarter of 1999.
Toggle Summary West Pharmaceutical Services, Inc. Comments on Second Quarter and 2000 Year - Announces Management Changes and Other Corporate Developments
LIONVILLE, Pa., June 21 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today reported that earnings for the second quarter ending June 30, 2000 and for the year are expected to be sharply lower than previously anticipated. The Company stated that the previously disclosed soft
West Pharmaceutical Services, Inc. Comments on Second Quarter and 2000 Year - Announces Management Changes and Other Corporate Developments
LIONVILLE, Pa., June 21 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today reported that earnings for the second quarter ending June 30, 2000 and for the year are expected to be sharply lower than previously anticipated. The Company stated that the previously disclosed soft
Toggle Summary West Pharmaceutical Services, Inc. Announces Dividend
LIONVILLE, Pa., June 20 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced that its Board of Directors has declared a dividend of $.17 per share for the third quarter of 2000 payable August 2, 2000 to shareholders of record July 19, 2000.
West Pharmaceutical Services, Inc. Announces Dividend
LIONVILLE, Pa., June 20 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced that its Board of Directors has declared a dividend of $.17 per share for the third quarter of 2000 payable August 2, 2000 to shareholders of record July 19, 2000.
Toggle Summary West Pharmaceutical Services, Inc. Announces First Quarter Results
LIONVILLE, Pa., April 19 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced results for the first quarter ended March 31, 2000. Sales for the first quarter were $107.7 million compared to the $114.2 million reported in the first quarter of 1999.
West Pharmaceutical Services, Inc. Announces First Quarter Results
LIONVILLE, Pa., April 19 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced results for the first quarter ended March 31, 2000. Sales for the first quarter were $107.7 million compared to the $114.2 million reported in the first quarter of 1999.
Toggle Summary West Pharmaceutical Services, Inc. Announces Dividend
LIONVILLE, Pa., March 27 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced that its Board of Directors has declared a dividend of $.17 per share for the second quarter of 2000 payable May 3, 2000 to shareholders of record April 19, 2000.
West Pharmaceutical Services, Inc. Announces Dividend
LIONVILLE, Pa., March 27 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced that its Board of Directors has declared a dividend of $.17 per share for the second quarter of 2000 payable May 3, 2000 to shareholders of record April 19, 2000.
Toggle Summary West Pharmaceutical Services, Inc. and Beaufor Ipsen, S.A. Enter Early-Stage Product Development Agreement
LIONVILLE, Pa., March 2 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced today that it has entered into a product development agreement with Beaufor Ipsen, S.A., a privately held French Pharmaceutical Group. The agreement involves the application of West's patented nasal
West Pharmaceutical Services, Inc. and Beaufor Ipsen, S.A. Enter Early-Stage Product Development Agreement
LIONVILLE, Pa., March 2 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced today that it has entered into a product development agreement with Beaufor Ipsen, S.A., a privately held French Pharmaceutical Group. The agreement involves the application of West's patented nasal
Toggle Summary West Pharmaceutical Services, Inc. Announces Fourth Quarter And Full Year 1999 Results
LIONVILLE, Pa., Feb. 15 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced results for the fourth quarter and year-ended December 31, 1999. Sales for the fourth quarter were $115.4 million, compared with $114.8 million reported in the fourth quarter of 1998.
West Pharmaceutical Services, Inc. Announces Fourth Quarter And Full Year 1999 Results
LIONVILLE, Pa., Feb. 15 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced results for the fourth quarter and year-ended December 31, 1999. Sales for the fourth quarter were $115.4 million, compared with $114.8 million reported in the fourth quarter of 1998.
Toggle Summary West Pharmaceutical Services Files IND Application For Nasal Leuprolide For The Treatment Of Endometriosis
LIONVILLE, Pa., Jan. 31 /PRNewswire/ -- West Pharmaceutical Services, Incorporated (NYSE: WST) announced today that it completed filling of an Investigational New Drug (IND) application covering a nasally administered formulation of leuprolide for the treatment of endometriosis and other selected
West Pharmaceutical Services Files IND Application For Nasal Leuprolide For The Treatment Of Endometriosis
LIONVILLE, Pa., Jan. 31 /PRNewswire/ -- West Pharmaceutical Services, Incorporated (NYSE: WST) announced today that it completed filling of an Investigational New Drug (IND) application covering a nasally administered formulation of leuprolide for the treatment of endometriosis and other selected
Toggle Summary West Pharmaceutical Services to Commence Phase I Clinical Trials for Nasal Morphine for Pain
LIONVILLE, Pa., Jan. 18 /PRNewswire/ -- West Pharmaceutical Services, Incorporated (NYSE: WST) announced today that its December 1999 IND (Investigational New Drug) application for a nasally administered formulation of morphine has now passed the FDA 30 day comment period, clearing the way for
West Pharmaceutical Services to Commence Phase I Clinical Trials for Nasal Morphine for Pain
LIONVILLE, Pa., Jan. 18 /PRNewswire/ -- West Pharmaceutical Services, Incorporated (NYSE: WST) announced today that its December 1999 IND (Investigational New Drug) application for a nasally administered formulation of morphine has now passed the FDA 30 day comment period, clearing the way for